3
Announcements
Trials
Browse
Landscape
Status
Completed
12
Terminated
3
Recruiting
2
Withdrawn
1
No longer available
1
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma
8
Recurrence
5
Lymphoma, Non-Hodgkin
5
Hodgkin Disease
4
Leukemia, Myeloid, Acute
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Precancerous Conditions
2
Neoplasms
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Extranodal NK-T-Cell
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Diseases
2
Primary Myelofibrosis
1
Primary Immunodeficiency Diseases
1
Preleukemia
1
Pancytopenia
1
Osteosclerosis
1
Osteopetrosis
1
Osteochondrodysplasias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Interventions
midostaurin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
Mastocytosis, Systemic
×
Lymphoid
×
Clear all
NCT05219266
2024-06-28
Managed Access Programs for PKC412, Midostaurin
Novartis
No longer available